Aptose Biosciences Establishes New At-The-Market Facility

NEXT STORY
CB2 Insights to Host Q12019 Earnings Call on May 31, 2019
PREV STORY
FDA approves Novartis Piqray® – the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Aptose Biosciences Establishes New At-The-Market Facility

NEXT STORY
CB2 Insights to Host Q12019 Earnings Call on May 31, 2019
PREV STORY
FDA approves Novartis Piqray® – the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Quantum Materials Announces QDX™ HealthID to Support Back-to-Work “Immunization Passport” Programs

author_avatar
NASDAQ Market News

Trillium Announces Management and Board Changes and Provides Corporate Update

author_avatar
NASDAQ Market News

VBL Therapeutics Announces the Launch of a New Clinical Trial of VB-111 Combined with the Checkpoint Inhibitor, Nivolumab, in Metastatic Colorectal Cancer

author_avatar
NASDAQ Market News